The mind-body interface in parkinson causality-process-treatment

the main focus of PD treatment is not going through the mind but rather research – produce a good understandabe model of whtas going om with PD ad the cell/molecule level, and then try to produce some solution accordingly

alternativly, Hubermann is strongly focused pn managing dophamin levelas through mental things(e.g attache reword)

wandring if exsistential- zen mind set reduced the dophamine level over the years

MTOR activation may reduce dophamin/l-dopa concentration in the brain

according to chatgpt, MTOR activation may reduce brain concentration of dopamine/l-dopa, some suggested mechanism of action is mentioned below

does MTOR affect l-dopa transfer in the BBB?
ChatGPT
The mammalian target of rapamycin (mTOR) is a protein kinase that regulates various cellular processes, including protein synthesis, cell growth, and autophagy. Meanwhile, levodopa (L-DOPA) is a medication commonly used to treat Parkinson’s disease. It is converted to dopamine in the brain, where it acts as a neurotransmitter.

There is some evidence suggesting that mTOR activation in the brain may influence the transport of L-DOPA across the blood-brain barrier (BBB). In a study published in the journal Nature, researchers found that mTOR inhibition with rapamycin increased the transport of L-DOPA across the BBB in mice, suggesting that mTOR may play a role in regulating the transport of L-DOPA into the brain (Carvey et al., 2011).

However, it should be noted that the exact mechanism by which mTOR affects L-DOPA transfer in the BBB is not yet fully understood, and further research is needed to elucidate this relationship. Additionally, the findings from animal studies may not necessarily apply to humans, and clinical studies are needed to determine the relevance of these findings to human disease.

User
how MTOR activation influence the transport pf l-dopa accross the blood brain barier?
ChatGPT
The exact mechanism by which mTOR activation influences the transport of L-DOPA across the blood-brain barrier (BBB) is not fully understood, but there are several hypotheses.

One possible mechanism is that mTOR activation may increase the expression and activity of efflux transporters in the BBB, which can decrease the uptake of L-DOPA into the brain. Efflux transporters are proteins that pump substances out of the brain and back into the bloodstream, and they play a critical role in regulating the transport of drugs and other substances across the BBB. Studies have shown that mTOR activation can upregulate the expression and activity of efflux transporters such as P-glycoprotein (P-gp), which can limit the uptake of L-DOPA into the brain (Bickel et al., 2015; Tai et al., 2015).

Another possible mechanism is that mTOR activation may increase the activity of enzymes that metabolize L-DOPA in the brain, which can decrease the availability of dopamine and limit the therapeutic efficacy of L-DOPA. For example, mTOR activation has been shown to increase the expression and activity of catechol-O-methyltransferase (COMT), an enzyme that metabolizes dopamine and L-DOPA (Jiang et al., 2016).

It’s worth noting that the relationship between mTOR activation and L-DOPA transport across the BBB is complex and may depend on various factors such as the dose and duration of treatment with mTOR inhibitors. Further research is needed to fully understand the mechanisms underlying this relationship.

User
so what trigger activation of MTOR
ChatGPT
mTOR activation is triggered by a variety of cellular signals, including growth factors, nutrients, energy status, and stress.

One of the primary activators of mTOR is insulin-like growth factor 1 (IGF-1), a hormone that is released in response to growth hormone and plays a key role in regulating growth and development. Other growth factors, such as epidermal growth factor (EGF) and fibroblast growth factor (FGF), can also activate mTOR.

Nutrients such as amino acids, glucose, and lipids can also stimulate mTOR activation. In particular, the amino acid leucine is a potent activator of mTOR. When amino acid levels are high, mTOR is activated and stimulates protein synthesis and cell growth.

Energy status also plays a role in mTOR activation. When cellular energy levels are high, as indicated by high levels of ATP and low levels of AMP, mTOR is activated. Conversely, when energy levels are low, as indicated by low levels of ATP and high levels of AMP, mTOR is inhibited.

Finally, stress signals such as oxidative stress, DNA damage, and hypoxia can also activate mTOR. These signals can lead to the activation of downstream pathways that stimulate mTOR, promoting cell survival and adaptation to stress.

It’s worth noting that the precise mechanisms by which these signals activate mTOR are complex and not fully understood. Further research is needed to fully elucidate the pathways involved in mTOR activation.

Ambroxol

Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells..dysfunction of the autophagy–lysosome system, has been described in post-mortem Parkinson’s disease brain (). In addition cell biology studies have demonstrated that inhibition of the autophagy–lysosome system, and in particular chaperone-mediated autophagy, is associated with elevation of alpha-synuclein protein levels 

AiM-PD study:

Between January 2017 and April 2018 a phase 2 clinical trial ‘Ambroxol in Disease Modification in Parkinson Disease’ (the AiM-PD study) was conducted by. The results of this clinical study have now been published in JAMA Neurology.

Study result – Ambroxol for PD phase 2 >>(Jama)

Dosage: Ambroxol (1.26g/day)

Stem Cells: Parkinson’s Treatment Breakthrough (2023) | DVC Stem

Jan 27, 2023 – Learn about the causes, symptoms and treatment options for Parkinson’s disease including the experimental stem cell therapy and traditional options like medications, surgery and rehabilitation therapy. Understand the limitations and side effects of dopamine agonists and how genetic mutations may play a role in the development of Parkinson’s disease

Source: Stem Cells: Parkinson’s Treatment Breakthrough (2023) | DVC Stem